ERK3 is a well-established bona fide tumour-promoting gene in lung cancer, particularly in association with PTEN deletion and KRAS mutation, and its overexpression in patient samples correlates poorly with patient survival (11, 13). This evidence concerns the gene KRAS and lung carcinoma.